• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $ZEAL

    Zealand Pharma A/S

    Subscribe to $ZEAL
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: zealandpharma.com

    Recent Analyst Ratings for Zealand Pharma A/S

    DatePrice TargetRatingAnalyst
    3/5/2024Buy
    Berenberg
    8/8/2023Equal-Weight
    Morgan Stanley
    11/16/2022Overweight → Equal-Weight
    Morgan Stanley
    1/11/2022Hold → Buy
    Jefferies
    See more ratings

    Zealand Pharma A/S Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Berenberg initiated coverage on Zealand Pharma

    Berenberg initiated coverage of Zealand Pharma with a rating of Buy

    3/5/24 7:30:01 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Zealand Pharma

    Morgan Stanley resumed coverage of Zealand Pharma with a rating of Equal-Weight

    8/8/23 7:40:54 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma downgraded by Morgan Stanley

    Morgan Stanley downgraded Zealand Pharma from Overweight to Equal-Weight

    11/16/22 9:37:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma upgraded by Jefferies

    Jefferies upgraded Zealand Pharma from Hold to Buy

    1/11/22 8:54:06 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma A/S Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zealand Pharma to participate in upcoming investor conferences in September 2025

    Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following investor conferences in September 2025. Jefferies Swiss Healthcare Summit 2025, September 3 in Zürich Adam Lange, Vice President, Investor Relations, will host investor meetings on Wednesday, September 3. Cantor Global Healthcare Conference 2025, September 3-5 in New York Adam Steensberg, President and Chief Executive

    8/28/25 11:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

    Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, August 20, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 20 August 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 19 August 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,115,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9.973% of the total share capital and 9.97

    8/20/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

    Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall;

    8/7/25 11:30:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

    Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V. Copenhagen, Denmark, July 18, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 18 July 2025 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder: As of 17 July 2025, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 7,135,191 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 10.001% of the total share capital and 10.001% o

    7/18/25 12:30:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Total number of shares and voting rights in Zealand Pharma as of June 30, 2025

    Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred. In Company Announcement No. 14 / 2025 dated June 6, 2025, Zealand Pharma announced a share capital increase due to the ex

    6/30/25 11:05:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide

    Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modificationsTreatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapiesUnique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammation Copenha

    6/18/25 11:29:44 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma increases its share capital as a result of the exercise of employee warrants

    Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

    6/6/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome

    Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) ("Zealand") (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for glepaglutide, a long-acting GLP-2 analog, for the treatment of adult patients with short bowel syndrome (SBS).   The submission of the MAA to the EMA for glepaglutide administered twice weekly for the treatme

    6/2/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

    Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 27, 2025 – Zealand Pharma A/S ("the Company" or "Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached fi

    5/27/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma A/S SEC Filings

    View All

    SEC Form 15F-12B filed by Zealand Pharma A/S

    15F-12B - Zealand Pharma A/S (0001674988) (Filer)

    9/30/22 5:24:36 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:20:13 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Zealand Pharma A/S

    S-8 POS - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 5:16:47 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25 filed by Zealand Pharma A/S

    25 - Zealand Pharma A/S (0001674988) (Filer)

    9/20/22 4:06:54 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zealand Pharma A/S

    6-K - Zealand Pharma A/S (0001674988) (Filer)

    9/7/22 4:07:52 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zealand Pharma A/S

    6-K - Zealand Pharma A/S (0001674988) (Filer)

    8/31/22 4:05:26 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zealand Pharma A/S

    6-K - Zealand Pharma A/S (0001674988) (Filer)

    8/26/22 10:21:22 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zealand Pharma A/S

    6-K - Zealand Pharma A/S (0001674988) (Filer)

    8/10/22 4:54:58 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Zealand Pharma A/S

    6-K - Zealand Pharma A/S (0001674988) (Filer)

    6/2/22 4:30:46 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Zealand Pharma A/S

    S-8 - Zealand Pharma A/S (0001674988) (Filer)

    5/25/22 9:11:27 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma A/S Financials

    Live finance-specific insights

    View All

    Zealand Pharma Announces Financial Results for the First Half of 2025

    Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025Petrelintide collaboration with Roche off to a strong start, while key leadership appointments and solid financial position enable exciting next chapter for Zealand Pharma. Collaboration and license agreement with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management off to a strong start, with further insight and updates expected at Roche's Pharma Day in September and Zealand Pharma's Capital Markets Day in December.Petrelintide program advancing at full speed, with ZUPREME Phase 2 trials progressing towards key milestones, and R

    8/14/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results

    Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on August 14, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the second quarter of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Kendall;

    8/7/25 11:30:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma increases its share capital as a result of the exercise of employee warrants

    Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S ("Zealand Pharma") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 292,508 divided into 292,508 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pha

    6/6/25 4:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the First Three Months of 2025

    Company announcement – No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabilities, and strategic partnership for petrelintide create strong foundation for accelerated growth. Entered historic and transformative partnership with Roche to co-develop and co-commercialize petrelintide as a future foundational therapy for weight management and rapidly expand into related indications, aiming to establish the leading amylin-based franchise.Enrolled the last participant in the large, global Phase 2 ZUPREME-1 trial with petrelintide in people with overweight or obesity, thre

    5/8/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results

    Press Release – No. 7 / 2025 Zealand Pharma conference call on May 8 at 2pm CET (8am ET) to present first quarter 2025 financial results Copenhagen, Denmark, May 1, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that it will host a conference call on May 8, 2025, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the first quarter / first three months of 2025. Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; Chief Medical Officer, David Ke

    5/1/25 11:05:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma increases its share capital as a result of the exercise of employee warrants

    Company announcement – No. 5 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, March 20, 2025 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has by decision of the Board of Directors increased its share capital by a nominal amount of DKK 27,425 divided into 27,425 new shares with a nominal value of DKK 1 each. The capital increase is a consequence of the exercise of warrants granted under two of Zealand Pharma's employee warrant programs. Employee warrant programs are part of Zealand Pharma's ince

    3/20/25 12:00:00 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity

    Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity The companies will co-develop and co-commercialize petrelintide monotherapy and potential combination products, including petrelintide/CT-388, in the U.S. and EuropeZealand Pharma will receive upfront cash payments of USD 1.65 billion, including USD 1.4 billion due at closing and USD 250 million in anniversary payments over two years, as well as potential milestone payments, for a total consideration of up to USD 5.3 billionProfits and losses will be shared on a 50/50 ba

    3/12/25 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the Full Year 2024

    Company announcement – No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeline, while building the foundation for accelerated growth in the years to come Positive results with long-acting amylin analog petrelintide in 16-week Phase 1b trial and advancement into large, comprehensive Phase 2b trial in people with overweight or obesity Positive topline results with GLP-1/GLP-2 receptor dual agonist dapiglutide in 13-week Phase 1b trial and expansion of trial to investigate higher doses over a longer treatment period Positive results with glucagon/GLP-1 receptor dual ag

    2/20/25 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Financial Results for the First Nine Months of 2024

    Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for Phase 2 backed by a solid financial position.   Presented extremely encouraging weight loss and tolerability data with long-acting amylin analog petrelintide from MAD Part 2 (16-week trial) at ObesityWeek 2024Announced positive topline results with GLP-1R/GLP-2R dual agonist dapiglutide from Part 1 of Phase 1b trial (13-week trial) Boehringer Ingelheim announced US FDA Breakthrough Therapy Designation and advancement to two large Phase 3 trials for survodutide in MASH Copenhagen, Denmark, Nov

    11/7/24 1:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

    Company announcement – No. 45 / 2024 Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants Copenhagen, Denmark, September 12, 2024 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has increased its share capital by a nominal amount of DKK 10,110 divided into 10,110 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under several of Zealand Pharma's employee warrant programs. The increase is a consequence of the exercise of warrants granted under two o

    9/12/24 11:01:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma A/S Leadership Updates

    Live Leadership Updates

    View All

    Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer

    Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078), a biotechnolog

    5/19/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery

    Press release – No. 5 / 2025 Zealand Pharma appoints Utpal Singh as Chief Scientific Officer to drive next-generation peptide therapeutics discovery Utpal joins Zealand Pharma at a pivotal moment as it aims to become a leader in the management of obesity and related complications He will lead the discovery and clinical translation of peptide medicines, investing in new technologies including data and computational science Utpal to expand the global scientific team to drive Zealand Pharma's next wave of highly differentiated, innovative therapies, building on the Company's strong drug development heritage Copenhagen, Denmark, 23 April 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)

    4/23/25 9:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers

    Company announcement – No. 40 / 2023 Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers Copenhagen, Denmark, November 30, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced the appointment of pharmaceutical industry veterans Enrique Conterno and Elaine Sullivan as observers to the company's board of directors. It is expected that Enrique Conterno and Elaine Sullivan will stand for election to Zealand Pharma's board of directors at the company's 2024 Annual General Meeting. "As board observes, Enrique and Elaine collectively bring decades

    11/30/23 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Appoints Henriette Wennicke as Chief Financial Officer

    COMPANY ANNOUNCEMENT – NO. 36 / 2022 Copenhagen, DK and Boston, MA, August 24, 2022 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of Henriette Wennicke as Zealand's Chief Financial Officer starting November 1, 2022. Henriette Wennicke comes to Zealand with broad finance and business experience at large organizations, including in healthcare, where she has led financial planning and R&D portfolio management. She is currently the Vice President and Head of Investor Relations and Treasury at GN Store Nord, a global leader in inte

    8/24/22 4:30:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer

    Press Release - No. 2/2022 Zealand Pharma Announces Appointment of David M. Kendall, M.D., as Chief Medical Officer David Kendall named Zealand Pharma CMOFollows Zealand Pharma's appointment of Adam Steensberg as CEO and decision to refocus strategyKendall has over 35 years of diabetes and metabolic disease experience including nearly two decades in the pharma industry Copenhagen, DK and Boston, MA, U.S. June 2, 2022 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the appointment of David M. Kendall, M.D., as Chief Medical Officer. Dr. Kendall most recently

    6/2/22 2:00:00 AM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zealand Pharma A/S Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zealand Pharma A/S (Amendment)

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/14/22 12:27:01 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Zealand Pharma A/S (0001674988) (Subject)

    2/3/21 1:13:21 PM ET
    $ZEAL
    Biotechnology: Pharmaceutical Preparations
    Health Care